- Home
- CTRN vs CLLS Comparison
CTRN vs CLLS Comparison
Compare CTRN & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTRN
- CLLS
- Stock Information
- Founded
- CTRN 1946
- CLLS 1999
- Country
- CTRN United States
- CLLS France
- Employees
- CTRN N/A
- CLLS N/A
- Industry
- CTRN Clothing/Shoe/Accessory Stores
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- CTRN Consumer Discretionary
- CLLS Health Care
- Exchange
- CTRN Nasdaq
- CLLS Nasdaq
- Market Cap
- CTRN 270.0M
- CLLS 299.0M
- IPO Year
- CTRN 2005
- CLLS 2007
- Fundamental
- Price
- CTRN $35.89
- CLLS $3.67
- Analyst Decision
- CTRN Buy
- CLLS Buy
- Analyst Count
- CTRN 2
- CLLS 1
- Target Price
- CTRN $31.50
- CLLS $8.00
- AVG Volume (30 Days)
- CTRN 87.5K
- CLLS 222.6K
- Earning Date
- CTRN 12-02-2025
- CLLS 11-03-2025
- Dividend Yield
- CTRN N/A
- CLLS N/A
- EPS Growth
- CTRN N/A
- CLLS N/A
- EPS
- CTRN N/A
- CLLS N/A
- Revenue
- CTRN $782,716,000.00
- CLLS $63,438,000.00
- Revenue This Year
- CTRN $8.16
- CLLS N/A
- Revenue Next Year
- CTRN $5.38
- CLLS $66.76
- P/E Ratio
- CTRN N/A
- CLLS N/A
- Revenue Growth
- CTRN 3.32
- CLLS 223.09
- 52 Week Low
- CTRN $16.18
- CLLS $1.10
- 52 Week High
- CTRN $39.37
- CLLS $5.48
- Technical
- Relative Strength Index (RSI)
- CTRN 58.32
- CLLS 50.34
- Support Level
- CTRN $35.12
- CLLS $3.93
- Resistance Level
- CTRN $36.90
- CLLS $5.48
- Average True Range (ATR)
- CTRN 1.77
- CLLS 0.39
- MACD
- CTRN 0.25
- CLLS -0.03
- Stochastic Oscillator
- CTRN 74.80
- CLLS 16.59
About CTRN Citi Trends Inc.
Citi Trends Inc is a retailer of urban fashion apparel and accessories in the United States. The company offers apparel, including fashion sportswear for men and women, as well as children, such as newborns, infants, toddlers, boys, and girls; accessories comprising handbags, jewelry, footwear, belts, intimate apparel, scrubs, and sleepwear; and functional and decorative home products, as well as beauty products, books and toys.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.